Trial Profile

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Lenvatinib (Primary) ; Rilvegostomig (Primary) ; Volrustomig (Primary) ; Cisplatin; Gemcitabine
Indications Biliary cancer; Liver cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms GEMINI-Hepatobiliary
Sponsors AstraZeneca

19 May 2025 According to the Compugen media release, company partner, AstraZeneca, plans to present early primary analysis of sub-study 2 (cohort A) from this study as poster presentations.
19 Feb 2025 Planned End Date changed from 26 Jan 2027 to 14 Dec 2026.
21 Nov 2024 Planned End Date changed from 14 Dec 2026 to 26 Jan 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com